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Available online xxxxThe orally active, α-hemoglobin derived hemopressin (PVNFKFLSH, Hp(1–9)) and its truncated (PVNFKFL,
Hp(1–7) and PVNFKF, Hp(1–6)) and extended ((R)VDPVNFKFLSH, VD-Hp(1–9) and RVD-Hp(1–9)) derivatives
have been postulated to be the endogenous peptide ligands of the cannabinoid receptor type 1 (CB1). In an
attempt to create a versatile peptidic research tool for the direct study of the CB1 receptor–peptide ligand inter-
actions, Hp(1–7)was radiolabeled and in vitro characterized in rat and CB1 knockoutmouse brainmembrane ho-
mogenates. In saturation and competition radioligand binding studies, [3H]Hp(1–7) labeledmembrane receptors
with high densities and displayed speciﬁc binding to a receptor protein, but seemingly not to the cannabinoid
type 1, in comparison the results with the prototypic JWH-018, AM251, rimonabant, Hp(1–9) and RVD-
Hp(1–9) (pepcan 12) ligands in both rat brain and CB1 knockout mouse brain homogenates. Furthermore, func-
tional [35S]GTP γS binding studies revealed that Hp(1–7) and Hp(1–9) only weakly activated G-proteins in both
brainmembrane homogenates. Based on our ﬁndings and the latest literature data, we assume that the Hp(1–7)
peptide fragment may be an allosteric ligand or indirect regulator of the endocannabinoid system rather than an
endogenous ligand of the CB1 receptor.
© 2016 Elsevier Ltd. All rights reserved.Keywords:
Hemopressin
Tritium labeling
Cannabinoid receptor
Radioligand binding assay
Ligand stimulated [35S]GTPγS binding assay1. Introduction
The endogenous, phyto- and synthetic cannabinoids exert their
pharmacological effects through the activation of cannabinoid recep-
tors. To date, the cannabinoid type 1 (CB1) and cannabinoid type 2
(CB2) receptors have been cloned that belong to the superfamily of
Gi/Go G-protein coupled receptors (Begg et al., 2005; Pertwee, 1997).
The CB1 receptors are primarily expressed in regions of the central ner-
vous system (Herkenham et al., 1990; Matsuda et al., 1990) while CB2
receptors proved to be localized mainly in immune cells of the periph-
ery (Munro et al., 1993), though recent studies reported the presence
of CB2 receptors in the brain stem and spinal cord as well (Van Sickle
et al., 2005; Zhang et al., 2003).-iodophenyl)-4-methyl-N-(1-
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6.02.001Lipid endocannabinoids are the best characterized endogenous
ligands of the cannabinoid receptors and their physiological effects
are primarily mediated through the CB1 receptors (Di Marzo and
Petrosino, 2007; Boyd, 2006). The activation of the CB1 receptor is
thought to be responsible for the mediation of antinociception, hypo-
thermia, hypotension, sedation and inhibition of locomotor activity
(Manzanares et al., 1999, Massi et al., 2001). Consequently, drugs acting
on the CB1 receptor and on the entire endocannabinoid system may
have therapeutic potential in a number of pathological conditions
such as obesity, metabolic syndromes, mood and anxiety disorders,
neuropathic pain, inﬂammation, multiple sclerosis, spinal cord injuries,
myocardial infarction, stroke, hypertension, cancer and osteoporosis
(Pacher et al., 2006).
Over the past decades, the lipid derived endocannabinoids were be-
lieved to be the sole endogenous agonists of the cannabinoid receptors.
However, as a result of the pioneering works of Heimann et al. (2007)
and Rioli et al. (2003), hemopressin (PVNFKFLSH, Hp(1–9)) was identi-
ﬁed as a putative inverse agonist peptide ligand of the CB1 receptor. This
peptide is a metabolic product of the hemoglobin α-chain and it was
demonstrated to exert non-opioid antinociceptive effects, similar to
those of the endo-, phyto- and synthetic cannabinoids (Heimann et al.,
2007; Hama and Sagen, 2011). In an in vivo model of arthritic pain
Hp(1–9) failed to mitigate mechanical allodynia (Petrovszki et al.,
2012), however, in other studies, it could prevent carrageen- and
bradykinin-induced hyperalgesia (Dale et al., 2005) and chronic con-
striction injury-induced mechanical hyperalgesia, a model of neuro-
pathic pain (Toniolo et al., 2014a, 2014b). Hp(1–9) was also reporteding and functional characteristics of hemopressin(1–7), Neuropeptides
2 S. Dvorácskó et al. / Neuropeptides xxx (2016) xxx–xxxto induce weak, but dose-dependent hypotensive effects and to reduce
food intake in rodents via a CB1 receptor-dependent manner (Blais
et al., 2005; Rioli et al., 2003; Dodd et al., 2010, 2013). Very recently,
Hp(1–9) was suggested promoting oligodendrocytic differentiation
and maturation of subventricular zone progenitor cells, of which pro-
cesses have signiﬁcance in myelination abnormalities (Xapelli et al.,
2014).
Soon after the discovery and pharmacological characterization of
Hp(1–9), the RVD- and VD-extended RVD-Hp(1–9) and VD-Hp(1–9)
(Gomes et al., 2009), and the C-terminally truncated Hp(1–6) and
Hp(1–7) peptides were identiﬁed as potent cannabinoid ligands (Dale
et al., 2005). RVD-Hp(1–9) and VD-Hp(1–9) were suggested being
agonist ligands of the CB1 receptor. In vivo data for the C-terminally
truncated hemopressins demonstrated that Hp(1–9) was not essential
for antinociceptive activity, because Hp(1–6) and Hp(1–7) exerted as
effective antihyperalgesic effects as theN-terminally extended peptides.
Further C-terminal truncation, however, led to the loss of biological ac-
tivity (Bomar and Galande, 2012). VD- and RVD-Hps exhibited
hypotensive, hypothermic and hypoactive effects at antinociceptive
doses, and inhibited bombesin-induced central activation of the
adrenomedullary outﬂow in rats (Tanaka et al., 2014; Han et al.,
2014). In addition, central administration of VD-Hp resulted in
tolerance to antinociception and stimulated food consumption in a
CB1-dependent manner (Han et al., 2014; Pan et al., 2014). The signal-
ing characteristics and regulation of receptor endocytosis of the
N-terminally extended peptide fragments were found to be distinct, in
part, from those of the classical cannabinoid agonists (Gomes et al.,
2009).
Circular dichroism, NMR spectroscopy and molecular docking stud-
ies on the Hp(1–9) and Hp(1–6) peptides showed that regular turn
structures in the central portion of the peptides were essential for an in-
teraction with the receptor, and similarly to the inverse agonist
rimonabant the peptides stabilized receptor structures via H-bonds
(Scrima et al., 2010). This interaction was assumed to be important for
the stabilization of the inactive state of CB1 receptor and provides struc-
tural basis for the explanation of the activity of hemopressin peptides as
agonist.
These observations suggest that hemopressins are novel endoge-
nous peptide ligands of the CB1 receptor, and may have potential for
the development of peptide-based research tools or therapeutic agents
for the study of the endocannabinoid system or the treatment of
cannabinoid-related diseases. In the present study, we report on the
synthesis and radiolabeling of the C-terminally truncated hemopressin
peptide Hp(1–7) and the direct in vitro pharmacological characteriza-
tion of the novel radioligand [3H]Hp(1–7) in brain membrane
homogenates of rat and CB1 knockout mouse. Our results suggest
that the hemoglobin fragment Hp(1–7) may be a regulator of the
endocannabinoid system and that [3H]Hp(1–7) can label either a CB
receptor binding site different from the classical cannabinoid ligand
binding site or another membrane protein.
2. Materials and methods
The peptides Hp(1–7) (H-Pro-Val-Asn-Phe-Lys-Phe-Leu-OH),
ΔPro1-Hp(1–7) (H-ΔPro-Val-Asn-Phe-Lys-Phe-Leu-OH), Hp(1–9) (H-
Pro-Val-Asn-Phe-Lys-Leu-Leu-Ser-His-OH) and RVD-Hp(1–9) (H-Arg-
Val-Asp-Pro-Val-Asn-Phe-Lys-Leu-Leu-Ser-His-OH) were synthesized
and puriﬁed in our laboratory. The peptide synthesis resins, protected
amino acids and the coupling reagent TBTU were purchased from
Bachem. Hydrogen ﬂuoride used for the cleavage of the peptides
was obtained from PRAXAIR N.V. (Oevel, Belgium). Naloxone and
rimonabant were kind gifts of Dr. Sándor Hosztaﬁ (Department of Phar-
maceutical Chemistry, Semmelweis University, Budapest, Hungary) and
Dr. Sándor Benyhe (Hungarian Academy of Sciences, Biological Re-
search Centre, Institute of Biochemistry, Szeged, Hungary). Analytical
grade AM251 was obtained from Cayman Chemicals. TFA and BSAPlease cite this article as: Dvorácskó, S., et al., Investigation of receptor bind
(2016), http://dx.doi.org/10.1016/j.npep.2016.02.001were purchased from Fisher Scientiﬁc. Protease inhibitor (cat#:
P2714), GDP, GTPγS, anisole, ninhydrin, magnesium chloride, EGTA
and Bradford reagent were purchased from Sigma-Aldrich Kft.
(Budapest, Hungary). Other reagents were obtained from Molar
Chemicals Kft. (Budapest, Hungary) or Merck Kft. (Budapest,
Hungary). Tritium gas was obtained from Technobexport (Moscow,
Russia). Tritium labeling was carried out in a self-designed vacuum
manifold and radioactivity was measured with a Packard Tri-Carb
2100 TR liquid scintillation analyzer using Hionic-Fluor scintillation
cocktail of PerkinElmer. Radio-HPLC was performed on a Jasco HPLC
system equipped with a Packard Radiomatic 505 TR Flow Scintillation
Analyser.
2.1. Preparation of hemopressins
The peptide synthesis was carried out manually in a silanized
glass reaction vessel. Nα-Boc-Leu-or Nα-Boc-His(Tos)-PAM resin
(0.15 mmol) was swollen for 30 min in DMF. After Boc-deprotection
with neat TFA and subsequent washings (three times with DMF and
iPrOH), TBTU activated Nα-Boc-protected amino acids (0.45 mmol)
were added for chain elongation in DMF and the unreacted resin-
bound peptides were end-capped with an excess of Ac2O in the pres-
ence of DIEA in DMF. Couplings were monitored with the Kaiser-test
(Kaiser et al., 1970). After removal of the N-terminal protecting group,
peptides were cleaved from the resinwith HF in the presence of anisole.
The crude peptide — resin mixtures were washed with diethylether,
then the peptides were dissolved in aqueous TFA and lyophilized. The
resulting crude peptideswere dissolved in aqueous TFA, and introduced
onto an analytical Vydac 218TP54 column and eluted using a linear gra-
dient of 1.5% per min of acetonitrile in water containing 0.1% TFA,
starting from 15% acetonitrile at a ﬂow rate of 1 mL/min, λ= 215 nm.
The same elution conditions were used for the puriﬁcation of the pep-
tides on a semipreparative Vydac 218TP1010 column at a ﬂow rate of
4 mL/min; isolated yields 56% (Hp(1–7)), 74% (ΔPro1-Hp(1–7)), 38%
(Hp(1–9)) and 42% (RVD-Hp(1–9)). Molecular weights of the peptides
were conﬁrmed byMALDI-TOFmass spectrometry (Hp(1–7) [M+H]+
864.42;ΔPro1-Hp(1–7) [M+H]+ 862.63; Hp(1–9) [M+H]+ 1089.26;
RVD-Hp(1–9) [M+ H]+ 1424.80).
2.2. Preparation of [3H]Hp(1–7)
The precursor peptide ΔPro1-Hp(1–7) (2 mg, 2.32 μmol) was dis-
solved in DMF and 3 mg Pd/BaSO4 catalyst was added to the solution.
The reaction mixture was degassed prior to tritium reduction by a
freeze–thaw cycle. Then it was stirred under 0.4 bar of tritium gas for
1 h at ambient temperature, followed by the ﬁltration of the catalyst
through a Whatman GF/C glass ﬁber ﬁlter. The ﬁltrate was evaporated
and labile tritiumwas removed by repeated evaporations from aqueous
EtOH solution. Finally 2.85 GBq of crude [3H]Hp(1–7) was obtained that
waspuriﬁed byHPLC. Quantitative analyses of the concentration and ra-
dioactivity of [3H]Hp(1–7) were performed by RP-HPLC via UV and ra-
dioactivity detection using a calibration curve made by Hp(1–7), and
the speciﬁc activity of [3H]Hp(1–7) was found to be 1.04 TBq/mmol
(28 Ci/mmol). The radioligand was aliquoted as ethanolic solutions
and stored in liquid nitrogen until application.
2.3. Preparation of brain membrane homogenates
Wistar rats (male, 180–220 g) were housed locally ad libitum and
handled according to the European Communities Council Directives
(86/609/ECC) and to the Hungarian Act for the Protection of Animals
in Research (XXVIII.tv. Section 32). Crude membrane fractions were
prepared from the brain without cerebellum. Brains were quickly re-
moved from the euthanized rats and directly put in ice-cold 50 mM
Tris/HCl (pH 7.4) buffer. The collected tissue was then homogenized
in 30 volumes (v/w) of ice-cold buffer with a Teﬂon-glass Brauning and functional characteristics of hemopressin(1–7), Neuropeptides
Fig. 1. (A.) Association time course of [3H]Hp(1–7) binding at 37 °C. 2 nM [3H]Hp(1–7)
was incubated with rat brain membrane for various time in the absence or presence of
10 μM Hp(1–7) to assess speciﬁc binding (■). (B.) Dissociation time course of
[3H]Hp(1–7) binding at 37 °C. 2 nM [3H]Hp(1–7) was incubated with rat brain
membrane for 30 min, then dissociation was initiated by the addition of 10 μM Hp(1–7)
after different time points. Data aremeans± S.E.M of at least 5 independent experiments.
3S. Dvorácskó et al. / Neuropeptides xxx (2016) xxx–xxxhomogenizer at the highest rpm. The homogenate was centrifuged at
20,000g for 25 min. The supernatant was discarded and the resulting
pellet was resuspended in 5 volumes (v/w) of ice-cold 50 mM Tris/
HCl (pH 7.4) buffer containing 0.32 M sucrose and stored in aliquots
in liquid nitrogen. Prior to the experiment, aliquots were thawed and
centrifuged at 20,000g for 25 min and the pellets were resuspended in
50 mM Tris/HCl (pH 7.4) containing 1% (w/v) BSA, homogenized with
a Dounce followed by the determination of the protein content by the
method of Bradford (Bradford, 1976). The membrane suspensions
were immediately used either in [35S]GTPγS functional assays or in
radioligand binding experiments. CD1 mouse brain homogenates re-
quired for the competition and [35S]GTPγS binding experiments on
CB1 knockout samples were kind gifts of Dr. Sándor Benyhe and Dr.
Ferenc Zádor (Biological Research Center, Institute of Biochemistry)
andwere processed as described above. The CB1 knockoutmouse strain
was generated as described by Ledent and co-workers (Ledent et al.,
1999).
2.4. Receptor binding assays
All binding experimentswere carried out at 37 °C in plastic tubes in a
ﬁnal volume of 1 mL 50mM Tris/HCl, 3 mMMgCl2 working buffer (pH:
7.4) that contained 0.2–0.5mg/mLmembrane protein and 1% (w/v) BSA
to reduce non-speciﬁc binding. Incubation mixtures were ﬁltered
through Whatman GF/B glass ﬁber ﬁlters with a Brandel Cell Harvester
(serial#: 2620) and ﬁlters were pre-soaked and washed three
times with 50 mM Tris/HCl (pH 7.4) washing buffer that contained
0.1% (w/v) BSA. Association kinetic curves were established by co-
incubating 2 nM [3H]Hp(1–7) with the membrane preparation in the
absence (total binding) or presence (non-speciﬁc binding) of 10 μM
Hp(1–7). Dissociation kinetic curves were determined after pre-
incubation of the membrane homogenate with 2 nM radioligand for
30 min in the presence of 1 mM EGTA, 1 mM EDTA, 2 mM PMSF and
0.1 mM bestatin to reach equilibrium, and then dissociationwas initiat-
ed by the addition of 10 μMHp(1–7) after the indicated periods of time.
The equilibrium dissociation constant (Kd) and the maximum number
of binding sites (Bmax) were determined by saturation binding experi-
ments performed with increasing concentrations of [3H]Hp(1–7)
(0.1–16/20 nM) in the absence (total binding) or presence (non-speciﬁc
binding) of 10 μM Hp(1–7). Competition binding studies were per-
formed by incubating the brain membrane homogenates of rat or CB1
knockout mouse with 2 nM [3H]Hp(1–7) in the presence of increasing
concentrations of various competing ligands (10−5 to 10−12 M) for
30 min at 37 °C. Non-speciﬁc binding was determined by the addition
of 10 μM Hp(1–7). The samples were incubated in a shaking water
bath and reactions were stopped by the addition of ice-cold washing
buffer followed by fast ﬁltration. The ﬁlters were immersed into an
Ultima Gold XR scintillation cocktail and radioactivity was measured
with a Packard Tri-Carb 2100 TR liquid scintillation analyzer.
2.5. Ligand stimulated [35S]GTPγ s binding assay
Rat brain membranes (30 μg protein/tube) were incubated with
0.05 nM [35S]GTPS (PerkinElmer) and with 10−10 to 10−6 M unlabeled
ligands in the presence of 30 μM GDP, 100 mM NaCl, 3 mMMgCl2 and
1 mM EGTA in 50 mM Tris/HCl buffer (pH 7.4) for 60 min at 30 °C.
Basal [35S]GTPγ S binding was measured in the absence of ligands and
was set as 100%. Nonspeciﬁc binding was determined by the addition
of 10 μM unlabeled GTPγS and subtracted from total binding. Incuba-
tion, ﬁltration and radioactivity measurement were carried out as
described above.
3. Data analysis
Results of the kinetic experiments are reported asmeans± S.E.M. of
at least three independent experiments each performed in duplicate.Please cite this article as: Dvorácskó, S., et al., Investigation of receptor bind
(2016), http://dx.doi.org/10.1016/j.npep.2016.02.001Non-linear regression analyses of the association and dissociation
curves and the direct saturation isotherms were performed to obtain
the observed association rate constant (kobs), the dissociation rate con-
stant (kd), the equilibrium dissociation constant (Kd) and the receptor
density (Bmax). In competition binding studies, the inhibitory constants
(Ki) were calculated from the inﬂection points of the displacement
curves using non-linear least-square curve ﬁtting and the Cheng-
Prusoff equation. All data and curves were analyzed by GraphPad
Prism 4.0 (San Diego, CA, USA). In [35S]GTPγS binding studies,
data were expressed as the percentage stimulation of the speciﬁc
[35S]GTPγS binding over the basal activity and are given as means ±
S.E.M. Each experiment was performed in triplicate and analyzed with
sigmoid dose–response curve ﬁtting to obtain potency (EC50) and efﬁ-
cacy (Emax) values. Statistical comparison was done by analysis of vari-
ance (one-way ANOVA) followed by the Bonferroni multiple
comparison test of GraphPad Prism 4.0 (San Diego, CA, USA), P b 0.05
was chosen to indicate signiﬁcant differences.
4. Results
4.1. Association and dissociation binding studies of [3H]Hp(1–7)
Association and dissociation binding assayswere performed to char-
acterize the interaction of [3H]Hp(1–7) withmembrane receptors using
rat brain membrane homogenate that is known to contain CB1 recep-
tors abundantly. Association binding experiments carried out in
the presence of 2 nM [3H]Hp(1–7) and a protein concentration of
0.45 mg/mL revealed speciﬁc binding of [3H]Hp(1–7) to rat brainmem-
branes at 37 °C. At this temperature, speciﬁc binding reached steady-ing and functional characteristics of hemopressin(1–7), Neuropeptides
Table 1
Kinetic parameters for [3H]Hp(1–7) in rat brain membrane
homogenate.
Kinetic parameters
Kobs (min−1) 1.08±0.12
Ka (nM−1 min−1) 0.119±0.001
Kd (min−1) 0.842±0.150
Kd (nM) 7.2±1.4
kobs is the observed pseudo-ﬁrst order rate constant, kd is the dis-
sociation rate constant, ka is the association rate constant calcu-
lated according to the following equation: ka = (kobs–kd)/
[radioligand]. Kd was calculated as follows: Kd = kd/ka. Data are
calculated from the average ± S.E.M of at least 3 independent
experiments
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bindingwas 50–60% of the total binding at 2 nM radioligand concentra-
tion under equilibrium conditions. Table 1 summarizes the calculated
equilibrium binding parameters. In the dissociation experiments, rat
brain membranes were incubated with 2 nM [3H]Hp(1–7) at 37 °C for
30 min and dissociation of the ligand–receptor complex was initiated
by the addition of 10 μM Hp(1–7) at different incubation time-points.
Dissociation proceeded with a monophasic kinetics (Fig. 1B.) providing
a dissociation rate constant (kd) of 0.842 ± 0.150 min−1. It was found
that 55% of the radioligand dissociated from the membranes. The kinet-
ically derived equilibriumdissociation constant (Kd) calculated from the
association and dissociation experiments was assessed to be 7.2 ±
1.2 nM under our experimental conditions.Fig. 2. Saturation isotherms of [3H]Hp(1–7). Increasing concentrations of the radioligand
were incubated with membrane homogenates of rat brain (A.) or CB1 knockout mouse
brain (B.) in the absence or presence of 10 μM Hp(1–7). Only speciﬁc binding data are
presented as means ± S.E.M of at least 3 independent experiments.
Please cite this article as: Dvorácskó, S., et al., Investigation of receptor bind
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Saturation radioligand binding experiments were carried out in
brain homogenates of rat and CB1 knockout mouse in the presence of
increasing radioligand concentrations for 30 min. The speciﬁc binding
of [3H]Hp(1–7) was found to be saturable and of high afﬁnity
(nanomolar range) in both tissue homogenates (Fig. 2A. and B.).
Single-site bindings were calculated for both saturation curves by
non-linear ﬁtting of the speciﬁc binding data points that resulted in dis-
sociation equilibrium constants (Kd) of 14.5 ± 3.2 nM and 10.8 ±
1.8 nM in rat and in CB1 knockoutmouse brainmembrane, respectively.
Furthermore, high receptor densities (Bmax = 830 ± 120 and 990 ±
145 fmol/mg protein in rat and in CB1 knockout mouse brain mem-
branes, respectively) were observed (Table 2). These Kd and Bmax values
suggested that the target receptor for the Hp(1–7) peptide was present
in both tissue homogenates and indicated the speciﬁc interaction of
[3H]Hp(1–7) with a highly abundant receptor protein.
4.3. Competitive binding studies of [3H]Hp(1–7)
The saturation binding experiments indicated that the binding
site of [3H]Hp(1–7) might be different from the CB1 receptor,
([3H]Hp(1–7) also displayed saturable binding in a CB1 knockout
brain homogenate) therefore we further characterized the labeled
Hp(1–7) in competition receptor binding assays in rat brain membrane
homogenate. First different non-peptidic cannabinoid agonists and
inverse agonists were used as competitor ligands (Fig. 3).
It was found that neither the non-selective cannabinoid full agonist
JWH-018, the CB1 receptor inverse agonist AM251 nor the CB1 receptor
inverse agonist rimonabant could displace the bound radioligand in rat
brain membranes. Only the unlabeled Hp(1–7) was able to compete
with its tritium labeled analog, with an apparently high inhibitory con-
stant of 103± 23 nM. In contrast, a Kd value of 14.5 ± 3.2 was obtained
by the analysis of the kinetic curves. Next, competition binding experi-
ments were performed to investigate the ability of hemopressins
Hp(1–7), Hp(1–9) and RVD-Hp(1–9) to inhibit the binding of
[3H]Hp(1–7) in rat brain membrane homogenate (Fig. 4A.).
These hemopressins could displace [3H]Hp(1–7) from the binding
site with different inhibitory constants (Table 3). The parent Hp(1–7)
displayed the highest afﬁnity (Ki = 111 ± 14 nM) to the binding site.
The Hp(1–9) peptide provided a slightly higher inhibitory constant
(Ki = 184 ± 28 nM) but still within the same order of magnitude.
These data indicated that Hp(1–7) and Hp(1–9) might bind to the
same site or conformation of a receptor protein, however both
Hp(1–9) and Hp(1–7) might prefer a receptor conformation or binding
site different from those of the non-peptidic cannabinoid agonists. In
contrast, the RVD-extended hemopressin (pepcan 12) displayed the
lowest binding afﬁnity (Ki = 1940 ± 121 nM) to the [3H]Hp(1–7)
labeled sites.
The ﬁndings of the saturation and competition binding studies
indicated the existence of a non-cannabinoid binding site or a receptor
protein. In order to provide further evidences for this assumption, the
ability of cannabinoid ligands and hemopressins to compete with
[3H]Hp(1–7) in CB1 knockout mouse brain membrane homogenate
was investigated (Fig. 4B.). It was found that Hp(1–7) displayed the
lowest inhibitory constant (Ki = 94 ± 25 nM), and this afﬁnity wasTable 2
Equilibrium binding data of [3H]Hp(1–7)
Tissue Kd (nM) Bmax (fmol/mg)
Rat brain membrane 11.8±2.2 830±120
CB1-KO mouse brain membrane 12.8±1.8 990±145
Dissociation equilibrium constants (Kd) and receptor densities (Bmax) were calculated by
ﬁtting of the saturation curves measured in brain membrane homogenates of wild-type
rat or CB1 knockout mouse in the absence or presence of 10 μM Hp(1–7). Data are
means ± S.E.M of at least 3 independent experiments.
ing and functional characteristics of hemopressin(1–7), Neuropeptides
Fig. 3. Competitive binding curves of [3H]Hp(1–7). Rat brain membrane was incubated
with 2 nM [3H]Hp(1–7) in the presence of 10−12–10−5 M of Hp(1–7) (●), rimonabant
(▲), AM251 (▼) or JWH-018 (♦) for 30 min at 37 °C. Non-speciﬁc binding was
measured in the presence of 10 μMHp(1–7), data are means ± S.E.M., n = 3.
Table 3
Inhibitory constants (Ki) of hemopressins against [3H]Hp(1–7) in rat brain
membrane homogenate.
Ligands Inhibitory constant (Ki), nM
Hp(1–7) 111 ± 14
Hp(1–9) 184 ± 28
RVD-Hp(1–9) 1940 ± 121
Hp(1–7) 94 ± 25
Hp(1–9) 401 ± 78
RVD-Hp(1–9) 3208 ± 396
Hemopressins were co-incubated with [3H]Hp(1–7) in brain homogenate of
rat or CB1 knockout mouse. Data are means ± S.E.M, n = 3.
5S. Dvorácskó et al. / Neuropeptides xxx (2016) xxx–xxxclose to that detected in rat brain membrane homogenate (Table 3.).
The similar afﬁnity values obtained for Hp(1–7) in the homologue dis-
placement studies both in rat and CB1 knockout mouse brain mem-
brane homogenates strongly suggest that the receptor of the Hp(1–7)
peptide has to be present in both tissue samples. Furthermore, the
higher differences in inhibitory constants (Ki = 184 ± 28 nM vs.
401 ± 78 nM) for the Hp(1–9) peptide in rat and CB1 knockout
mouse brain homogenates may refer to binding to different regions of
the same receptor in the two species or binding to the same region of
the receptors with sequence heterogeneity in the two mammalian spe-
cies. Similarly to theﬁndings inwhole rat brainmembranehomogenate,Fig. 4. Competitive binding curves of [3H]Hp(1–7) by various hemopressins. Brain
membranes of rat (A.) or CB1 knockout mouse (B.) were co-incubated with 2 nM
[3H]Hp(1–7) in the presence of 10−12–10−5 M of Hp(1–7) (●), Hp(1–9) (▲) or RVD-
Hp(1–9) (▼). Non-speciﬁc binding was measured in the presence of 10 μM Hp(1–7).
Data are means ± S.E.M., n = 3.
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3208 ± 396 nM) to the [3H]Hp(1–7) labeled sites.
4.4. Ligand stimulated [35S]GTPγs binding studies
Since hemopressins were reported to be the agonist ligands of the
CB1 receptor, we were curious about how Hp(1–7) and Hp(1–9) acti-
vate G-proteins. The CB1 receptor full agonist JWH-018 and the inverse
agonist rimonabant were applied as positive controls to validate the
conditions of the ligand stimulated [35S]GTPγS binding assay in rat
brain membranes. JWH-018 stimulated [35S]GTPγS binding with theFig. 5. [35S]GTPγS binding stimulated by Hp(1–7), Hp(1–9) and cannabinoid ligands in rat
brain membrane homogenate. JWH-018 and rimonabant were used as positive controls.
Rat brain membranes were incubated with 0.05 nM [35S]GTPγS in the presence of
10−12–10−5 M Hp(1–7) (■), Hp(1–9) (▲), JWH-018 (▼) or rimonabant (●). Non-
speciﬁc binding was measured with 10 μM GTPγS. Data are expressed as means ±
S.E.M., n = 3. Signiﬁcant differences were deﬁned as P b 0.05.
ing and functional characteristics of hemopressin(1–7), Neuropeptides
Fig. 6. [35S]GTPγS binding stimulated by DAMGO, Hp(1–7) and Hp(1–9) in CB1 knockout
mouse brain membrane homogenate. Mouse brain membranes were incubated with
0.05 nM [35S]GTPγS in the presence of 10−12–10−5 M DAMGO (■), Hp(1–7) (▲) or
Hp(1–9) (▼). Non-speciﬁc binding was measured in the presence of 10 μM GTPγS. Data
are means ± S.E.M., n = 3.
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1.2 nM) in good agreement with literature data (Atwood et al., 2010)
(Fig. 5.). Rimonabant also behaved as described in the literature
(Zador et al., 2014). The Hp(1–7) peptide displayed low potency
(EC50 = 21 ± 1.5 nM) and marginal stimulatory activity (Emax =
112 ± 8%) as compared to the well-known non-peptidic cannabinoids
(Fig. 5 and Table 4). Hp(1–9) also showed low potency (EC50 = 29 ±
3.5 nM), but did not activate [35S]GTPγS binding (Emax = 104 ± 7%).
Next, Hp(1–7) and Hp(1–9) were tested in [35S]GTPγS binding assays
using membranes prepared from the brain of CB1 knockout mice. We
used the opioid full agonist DAMGO as a positive control to compare
[35S]GTPγS activation and to test the validity of our experimental
model (Fig. 6 and Table 5).
The agonist control compound DAMGO exhibited low potency
(EC50 = 177 ± 21 nM) and signiﬁcant stimulation (Emax = 167 ±
20%) of [35S]GTPγS binding as compared to Hp(1–7) and Hp(1–9).
The Hp(1–7) peptide demonstrated a higher potency value (EC50 =
655 ± 98 nM), in comparison with the potency obtained in rat brain
membrane homogenate. However, Hp(1–7) displayed very similar
stimulatory effects in both wild type rat brain and CB1 knockout
mouse brain homogenates (Emax= 112±12 and 117±18%). Similarly
to the competitive displacement studies this ﬁnding suggests that the li-
gand activates a G-protein or binds to a protein through the same bind-
ing site or receptor protein(s) that is/are present in both types of tissues.
Consequently, its main target protein cannot be the CB1 receptor be-
cause it is not supposed to be present in the brain membrane prepara-
tion of CB1 knockout mice. The Hp(1–9) peptide showed higher
potency (EC50 = 65 ± 12 nM), but a stimulatory effect (Emax =
111 ± 17%) roughly equivalent with that of the Hp(1–7) peptide. This
difference in thepotency valuemay reﬂect different bindingmode or in-
teraction of the Hp(1–9) peptide with its binding partner.
5. Discussion
The endocannabinoid system is involved in the regulation of many
physiological and pathological processes, therefore, a better under-
standing of its function is of high importance (Pacher et al., 2006). The
recently discovered α-hemoglobin derived hemopressins have been
postulated to be negative allostericmodulators and endogenous agonist
ligands of the CB1 receptors. These peptides have been demonstrated to
possess in vitro and in vivo pharmacological potencies similar to those of
the prototypic endogenous and synthetic cannabinoid ligands, but with
less side-effects (Dale et al., 2005; Heimann et al., 2007; Gomes et al.,
2009; Bomar and Galande, 2012). Accordingly, hemopressins have ap-
peared to be excellent lead compounds for the development of peptidic
research tools for the investigation of the endocannabinoid system.
Their reported pharmacological characteristics have prompted us to
prepare a radiolabeled peptide ligand that acts on the CB1 receptor
and thus, enables the direct investigation of the endocannabinoid sys-
tem and the binding properties of new synthetic CB1 receptor ligands.
The Hp(1–9) peptide and its extended or truncated derivativeswere
demonstrated to be orally active and to exert antinociceptive effects
that were apparently mediated by the CB1 receptors (Bomar and
Galande, 2012). The physiological activity upon oral administration sug-
gests that these peptides are at least partially resistant to proteolysis,Table 4
Summary of the results of [35S]GTPγS functional binding assays in rat brain membrane
preparation.
Ligands EC50 (nM) Emax (%)
Hp(1–7) 21 ± 1.5 112 ± 8
JWH-018 9.5 ± 1.2 165 ± 25
Hp(1–9) 29 ± 3.5 104 ± 7
Rimonabant 539 ± 65 46 ± 7
Nonspeciﬁc binding was determined by the addition of 10 μM unlabeled GTPγS. Data are
means ± S.E.M, n = 3, each performed in triplicate.
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these favorable characteristics and to the fact that the truncated
Hp(1–7) peptide was also found to be as potent as Hp(1–9) in in vitro
and in vivo studies (Heimann et al., 2007), Hp(1–7) was chosen for
radiolabeling without any structural modiﬁcation.
The tritium labeled Hp(1–7) was investigated in various radioligand
binding assays to characterize the interaction of Hp(1–7) and CB recep-
tors. Data analysis of receptor binding kinetics of [3H]Hp(1–7) showed
that the radioligand reaches equilibrium and steady-state very fast
under the experimental conditions. Saturation binding experiments re-
vealed single-site binding and very high receptor densities in both wild
type rat brainmembrane andCB1 knockoutmouse brainmembrane ho-
mogenates. In displacement studies, the radioligand was not able to
compete with the most commonly used CB1 receptor agonist/inverse
agonist cannabinoid ligands. However, we found competition with
Hp(1–9) in both types of brain homogenates which suggests that both
Hp(1–7) and Hp(1–9)may be able to bind to the same receptor binding
pocket or allosteric site. This result is contradictory because the CB1Table 5
Summary of the results of [35S]GTPγS functional binding assay in CB1 knockout mouse
brain membrane preparation.
Ligands EC50 (nM) Emax (%)
DAMGO 177 ± 21 167 ± 20
Hp(1–7) 655 ± 98 117 ± 18
Hp(1–9) 65 ± 12 111 ± 17
Nonspeciﬁc binding was determined by the addition of 10 μM unlabeled GTPγS. Data are
means ± S.E.M, n = 3, each performed in triplicate.
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ceptors. Nonetheless, the presence of allosteric binding site on CB1 re-
ceptors for hemopressins has been demonstrated (Bauer et al., 2012,
Straiker et al., 2015).
More than 400 different GPCRs have been shown to be encoded in
the human genome. Many of them, such as the muscarinic acetylcho-
line, adenosine, α-adrenergic, bombesin, melatonin, melanocortin,
neurotensin, neuromedin, orexin, galanin, opioid, serotonin and
tachykinin receptors have been reported tomediate either hypotensive,
antinociceptive and/or antihyperalgesic effects through inhibitory or
stimulatory pathways (Stone and Molliver, 2009). Though, the abun-
dance of these mainly neuropeptide receptors is usually much lower
than that observed for the CB1 in the brain, these receptors may serve
as speciﬁc or non-speciﬁc binding partners for Hp(1–7), and can be
highly expressed inmammalian brains under physiological or patholog-
ical conditions. There are many observations supporting the evidence
that hemopressins may indirectly regulate the function of other GPCRs
and mediate their analgesic, antihyperalgesic and hypotensive effects
likely through one or more of these receptor proteins or ion channels.
Indeed, a recent exciting study has pointed to the role of TRPV1, a
non-selective ligand-gated cation channel that has been proven to pro-
mote central anxiogenic effects in animal model of anxiety following
i.c.v. administration of Hp(1–9) (Fogaça et al., 2015). This effect could
be blocked by the addition of a TRPV1 antagonist further demonstrating
the fact that the observed effects were mediated via a CB1 receptor-
independent manner. In our functional [35S]GTPγS binding experi-
ments, Hp(1–7) and Hp(1–9) behaved as very weak agonists (if at
all), and could not stimulate [35S]GTPγS binding signiﬁcantly. Recently,
a very similar [35S]GTPγS stimulatory effect was observed in competi-
tive radioligand and [35S]GTPγS binding studies (Szlavicz et al., 2015).
It was found that Hp(1–7) and Hp(1–9) slightly activated G-proteins
in a naloxone-sensitive manner and that the peptides directly
interacted with the CB1 and MOP receptors as well. These results sup-
port our hypothesis that hemopressins can directly or indirectly interact
with other G-protein coupled receptors in different in vitromodel sys-
tems and emphasize the importance of the implied experimental
model. The brain derived neuropeptide FF (NPFF) and its receptors are
well-known modulators of the opioid system. This system was shown
to interact with the CB1 receptor as well. NPFF has recently been pub-
lished to modulate cannabinoid-induced antinociception after i.c.v. ad-
ministration of mouse VD-hemopressin(α) (an extended analog of
Hp(1–9)) in naive and VD-hemopressin(α) tolerant mice (Pan et al.,
2015). In naivemice, i.c.v. injection of NPFF dose-dependently attenuat-
ed central analgesia of VD-hemopressin(α). The VD-hemopressin(α)-
modulating activities of NPFF and related peptides could be antagonized
by NPFF receptor selective antagonists. These results indicate a direct
interaction between hemopressins and the NPFF system. Galanin is an-
other GPCR-acting neuropeptide that is widely expressed in the brain
and is a common inhibitor of action potential in neurons. Hofer and
co-workers have recently found co-localization and production of this
neuropeptide with peptide endocannabinoids (pepcans) in speciﬁc re-
gions of the rodent CNS (Hofer et al., 2015). They found enhanced im-
munostaining and co-localization of RVD-Hp(1–9) (pepcan 12) with
galanin in the hippocampus and cerebral cortex, along with the antero-
grade axonal bundles. However, no immunolabeling could be detected
in dopaminergic neurons. These ﬁndings further conﬁrm the fact that
hemopressins can widely interact with various endogenous neuropep-
tide systems and can co-regulate pain perception and alleviation.
Based on our direct in vitro receptor binding results and the large
number of literature data, we hypothesize that hemopressins indirectly
interact with the CB1 receptor. They more likely up-regulate the
endocannabinoid production and the subsequent endocannabinoid re-
lease may be responsible for the observed analgesic effects. This as-
sumption seems to be further supported by the study of Toniolo and
co-workers (Toniolo et al., 2014a, 2014b). They found that hemopressin
could inhibit monoacylglycerol-lipase activity in dorsal root ganglionsPlease cite this article as: Dvorácskó, S., et al., Investigation of receptor bind
(2016), http://dx.doi.org/10.1016/j.npep.2016.02.001and this might lead to an increase of 2-arachidonoyl-glycerol inducing
analgesia. They also hypothesized that hemopressin can interact with
the peripheral voltage-gated potassium channels and reduce calcium
inﬂux in a synergistic manner with the peripheral cannabinoid recep-
tors. It was also concluded that hemopressin can induce an increase of
endocannabinoid level and this would, in turn, lead to the activation
of descending inhibitory pain pathways inducing analgesia. However,
we cannot fully exclude the existence of allosteric binding site for
hemopressins, especially based on the recent ﬁndings of Straiker and
co-workers (Straiker et al., 2015). They studied positive and negative
allosteric modulators of the endocannabinoid-mediated synaptic trans-
mission in cultured hippocampal neurons. In their study, RVD-Hp(1–9)
that did not apparently exhibit binding to the CB1 receptor in our sys-
tem attenuated depolarization-induced suppression of excitation. Inter-
estingly, Hp(1–9) was ineffective in this model of endocannabinoid
signaling. These outcomes shed light on the importance of the implied
model system and on variations between the potencies and interaction
of endocannabinoids/pepcans with their respective receptors.
Since hemopressins have been reported to possess outstanding
pharmacological properties in many in vivo models, further in-depth
in vitro and in vivo studies will be necessary for the delineation of
Hp(1–7) binding site and its pharmacological signiﬁcance in mammali-
an species.
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